Zydus vaccine launch likely to be delayed due to issues at plant – ET HealthWorld

The launch of Zydus Cadila‘s Covid-19 vaccine – ZyCoV-D – is expected to be delayed by a few more weeks due to issues in scaling up production at its plant in Ahmedabad, people in the know told ET. Zydus Cadila managing director Sharvil Patel had said previously that the company would be able to manufacture 10 million doses by October 2021 and 40-50 million doses by January this year. “Complex products take time,” one of the people said, adding that “DNA products have never been made at this scale”. Zydus…

Read More

Right pricing to hold the key for Zydus Cadila’s vaccine launch – ET HealthWorld

The recommendation of the subject expert committee (SEC) for the grant of marketing authorisation for Bharat Biotech‘s Covaxin for 2-18-year-old children has put the fate of Zydus Cadila vaccine rollout in question, as the price of the vaccine seems to be holding up its induction in the vaccination programme. Zydus Cadila has the drug regulator’s emergency use authorisation to administer its Covid vaccine, ZyCoV-D, in children aged 12-18 years. As Covaxin is set to become available for the same age group as well, the bargaining position of the government will…

Read More

Zydus Cadila likely to get emergency use approval for its COVID vaccine this week: Sources – ET HealthWorld

Ahmedabad-based Zydus Cadila‘s three-dose COVID-19 vaccine ZyCoV-D is expected to get an emergency-use nod from the expert committee this week, sources said. Union Health Minister Mansukh Mandaviya last week during the question hour in the Rajya Sabha had said, “The government expects that in October-November, four more Indian pharmaceutical companies will start production of indigenous vaccines that will help to meet the domestic demand, Biological E and Novartis vaccines will also be available in the market in the coming days, while Zydus Cadila will soon get an emergency use nod…

Read More